Literature DB >> 14569210

Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies.

Michelle L Harris1, Antony Rosen.   

Abstract

PURPOSE OF REVIEW: Systemic sclerosis, or scleroderma, is a systemic autoimmune disease manifest by vascular damage and fibrosis within the skin and visceral organs. Whereas scleroderma is a heterogenous disorder in terms of disease symptoms and clinical course, scleroderma-specific autoantibody profiles associate strongly with distinct clinical phenotypes, making serologic testing of great diagnostic aid. This review will focus on the clinical significance and the potential pathogenic role of autoantibodies in scleroderma. RECENT
FINDINGS: Novel autoantibody and phenotype associations discovered within the past year underscore the clinical utility of systemic sclerosis-associated autoantibodies. Whereas autoantibodies are generally believed to indicate the presence of ongoing tissue damage, some research suggests that the humoral immune response may play a role in generating such damage.
SUMMARY: Improvements in multiplex autoantibody assays will aid in the diagnosis and prognosis of the complications associated with systemic sclerosis. Continued research into autoantibody/phenotype associations could also yield critical insights into the pathogenesis of, and suggest novel therapeutic targets for, this chronic, debilitating disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14569210     DOI: 10.1097/00002281-200311000-00016

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  27 in total

1.  [Systemic sclerosis].

Authors:  S Kleinert; H P Tony; C Kneitz
Journal:  Internist (Berl)       Date:  2006-10       Impact factor: 0.743

Review 2.  Autoantigens in systemic autoimmunity: critical partner in pathogenesis.

Authors:  A Rosen; L Casciola-Rosen
Journal:  J Intern Med       Date:  2009-06       Impact factor: 8.989

3.  Activation of autoreactive B cells by endogenous TLR7 and TLR3 RNA ligands.

Authors:  Nathaniel M Green; Krishna-Sulayman Moody; Michelle Debatis; Ann Marshak-Rothstein
Journal:  J Biol Chem       Date:  2012-09-27       Impact factor: 5.157

Review 4.  The pathogenesis of systemic sclerosis revisited.

Authors:  Matthias Geyer; Ulf Müller-Ladner
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

Review 5.  My approach to the treatment of scleroderma.

Authors:  Ami A Shah; Fredrick M Wigley
Journal:  Mayo Clin Proc       Date:  2013-04       Impact factor: 7.616

6.  Coexistence of systemic sclerosis with other autoimmune diseases.

Authors:  Paola Caramaschi; Domenico Biasi; Alessandro Volpe; Antonio Carletto; Melissa Cecchetto; Lisa Maria Bambara
Journal:  Rheumatol Int       Date:  2006-09-19       Impact factor: 2.631

7.  Association of the autoimmune disease scleroderma with an immunologic response to cancer.

Authors:  Christine G Joseph; Erika Darrah; Ami A Shah; Andrew D Skora; Livia A Casciola-Rosen; Fredrick M Wigley; Francesco Boin; Andrea Fava; Chris Thoburn; Isaac Kinde; Yuchen Jiao; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Antony Rosen
Journal:  Science       Date:  2013-12-05       Impact factor: 47.728

Review 8.  B cells and transplantation: an educational resource.

Authors:  Trudy N Small; William H Robinson; David B Miklos
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

Review 9.  Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis.

Authors:  Alfred Grassegger; Gabriela Pohla-Gubo; Margret Frauscher; Helmut Hintner
Journal:  Wien Med Wochenschr       Date:  2008

10.  Potential role of human-specific genes, human-specific microRNAs and human-specific non-coding regulatory RNAs in the pathogenesis of systemic sclerosis and Sjögren's syndrome.

Authors:  Sergio A Jimenez; Sonsoles Piera-Velazquez
Journal:  Autoimmun Rev       Date:  2013-05-15       Impact factor: 9.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.